Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 35 | ECE2014 | Next issue

16th European Congress of Endocrinology


Cushings syndrome

ea0035s17.1 | Cushings syndrome | ECE2014

Mortality: still increased despite cure in Cushing’s disease?

Dekkers Olaf

There is considerable evidence that mortality is increased in patients with CushingÂ’s syndrome of pituitary origin. This is thought to be caused by long-term exposure to supraphysiological cortisol levels inducing harmful effects, such as hypercoagulability, insulin resistance, hypertension, bone loss, and immunosuppression. It is assumed that some cortisol-related effects persist after treatment and the important question is whether this translates in an increased mortal...

ea0035s17.2 | Cushings syndrome | ECE2014

Abstract unavailable....

ea0035s17.3 | Cushings syndrome | ECE2014

Medical therapy for endogenous hypercortisolism

Findling James

The initial therapy for endogenous hypercortisolism (EH) or CushingÂ’s syndrome (CS) is almost always surgery. However, persistence or recurrence of EH is common and medical therapy may be needed to control the clinical and metabolic derangements associated with EH. Pituitary directed therapies include: Cabergoline, simple and well tolerated, cortisol (F) is normalized in 25-40% of patients but the effect is usually not enduring and Pasireotide, a somatostatin analog, redu...